新着動画一覧

(TEAR, BLRX, PLCM) CRWENewswire Stocks In Action

BioLineRx Ltd -BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. On its Fourth quarter fiscal 2011, Polycom Inc - PLCM - posted record consolidated net revenues of $407 million, compared to $340 million in the same period the prior year. and lastly; TearLab Corp - TEAR - reported that after reviewing and accepting labeling submitted to it by the Company, the FDA has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 for the TearLab Osmolarity System. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者： karmastock
投稿日時：2012-01-25 04:39:01.0
視聴回数：409回
お気に入り登録：0
カテゴリ： ビジネス全般  
タグ： PLCM   TEAR   BLRX   Nasdaq:BLRX   Nasdaq:TEAR   Nasdaq:PLCM